关键词: HPV shared-decision making HPV vaccine uptake Human papillomavirus (HPV) National Health Interview Survey (NHIS) adults aged 27–45 years expanded HPV vaccine eligibility racial disparities

Mesh : Male Adult Female Humans United States Papillomavirus Infections / prevention & control Papillomavirus Vaccines Cross-Sectional Studies Racial Groups Human Papillomavirus Viruses Vaccination Healthcare Disparities

来  源:   DOI:10.1080/21645515.2024.2313249   PDF(Pubmed)

Abstract:
In 2018, the Food and Drug Administration expanded the age of eligibility for the human papillomavirus (HPV) vaccine to 27 to 45 years. However, it is unclear if there are racial/ethnic disparities in HPV vaccine uptake for this age-group following this expanded recommendation. We aimed to identify any disparities in HPV vaccine in 27 to 45 year-olds based on sociodemographic factors. We analyzed nationally representative, cross-sectional data from the 2019 National Health Interview Survey (n = 9440). Logistic regression models estimated the odds of vaccine uptake (receipt of ≥1 vaccine dose) based on sociodemographic factors. Participants were mostly Non-Hispanic Whites (60.7%) and females (50.9%). In adjusted models, females had over three times greater odds of vaccine uptake compared to males (aOR = 3.58; 95% CI 3.03, 4.23). Also, compared to Non-Hispanic Whites, Non-Hispanic Blacks were 36% more likely (aOR = 1.36; 95% CI 1.09, 1.70), and Hispanics were 27% less likely (aOR = 0.73; 95% CI 0.58, 0.92) to receive the vaccine. Additionally, individuals without a usual place of care had lower odds of vaccine uptake (aOR = 0.72; 95% CI 0.57, 0.93), as were those with lower educational levels (aORhigh school = 0.62; 95% CI 0.50, 0.78; aORsome college = 0.83; 95% CI 0.70, 0.98). There are disparities in HPV vaccine uptake among 27 to 45 year-olds, and adult Hispanics have lower odds of receiving the vaccine. Given the vaccine\'s importance in cancer prevention, it is critical that these disparities are addressed and mitigated.
摘要:
2018年,美国食品和药物管理局将人乳头瘤病毒(HPV)疫苗的合格年龄扩大到27至45岁。然而,目前尚不清楚在这项扩大推荐后,该年龄组的HPV疫苗接种是否存在种族/族裔差异.我们旨在根据社会人口统计学因素确定27至45岁人群中HPV疫苗的任何差异。我们分析了具有全国代表性的,2019年全国健康访谈调查的横截面数据(n=9440)。Logistic回归模型基于社会人口统计学因素估计疫苗摄取(接受≥1次疫苗剂量)的几率。参与者主要是非西班牙裔白人(60.7%)和女性(50.9%)。在调整后的模型中,女性接种疫苗的几率是男性的3倍以上(aOR=3.58;95%CI3.03,4.23).此外,与非西班牙裔白人相比,非西班牙裔黑人的可能性更高36%(aOR=1.36;95%CI1.09,1.70),西班牙裔人接种疫苗的可能性降低了27%(aOR=0.73;95%CI0.58,0.92).此外,没有常规护理场所的个体接种疫苗的几率较低(aOR=0.72;95%CI0.57,0.93),受教育程度较低的人也是如此(aOR高中=0.62;95%CI0.50,0.78;aOR大学=0.83;95%CI0.70,0.98).在27至45岁的人群中,HPV疫苗的摄取存在差异。成年西班牙裔人接种疫苗的几率较低。鉴于疫苗在癌症预防中的重要性,解决和减轻这些差距至关重要。
公众号